2020
Cost-Effectiveness of Neoadjuvant-Adjuvant Treatment Strategies for Women With ERBB2 (HER2)–Positive Breast Cancer
Kunst N, Wang SY, Hood A, Mougalian SS, DiGiovanna MP, Adelson K, Pusztai L. Cost-Effectiveness of Neoadjuvant-Adjuvant Treatment Strategies for Women With ERBB2 (HER2)–Positive Breast Cancer. JAMA Network Open 2020, 3: e2027074. PMID: 33226431, PMCID: PMC7684449, DOI: 10.1001/jamanetworkopen.2020.27074.Peer-Reviewed Original ResearchMeSH KeywordsAdo-Trastuzumab EmtansineAdultAgedAnthracyclinesAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalAntineoplastic Agents, PhytogenicBreast NeoplasmsCase-Control StudiesCost-Benefit AnalysisCross-Linking ReagentsDrug Therapy, CombinationFemaleHumansImmunosuppressive AgentsMiddle AgedNeoadjuvant TherapyPaclitaxelQuality-Adjusted Life YearsReceptor, ErbB-2TrastuzumabTubulin ModulatorsUnited StatesConceptsErbB2-positive breast cancerAdjuvant treatment strategiesAdjuvant T-DM1Pathologic complete responseT-DM1Treatment strategiesBreast cancerKATHERINE trialResidual diseaseNeoadjuvant regimenHigher health benefitsHealth care payer perspectiveAdjuvant trastuzumab emtansineAnthracycline/cyclophosphamideDifferent adjuvant therapiesFlatiron Health databaseIncremental cost-effectiveness ratioNeoadjuvant treatment optionsHealth benefitsPositive breast cancerCare payer perspectiveCost-effectiveness ratioBase-case analysisDecision analytic modelH. Patients
2008
Paclitaxel-induced sickle cell crisis
Wilson NM, Espirito JL, Valero V, Pusztai L. Paclitaxel-induced sickle cell crisis. American Journal Of Health-System Pharmacy 2008, 65: 1333-1336. PMID: 18593679, DOI: 10.2146/ajhp070432.Peer-Reviewed Original ResearchMeSH KeywordsAnemia, Sickle CellAntineoplastic Agents, PhytogenicBlack or African AmericanBreast NeoplasmsFemaleHumansMiddle AgedPaclitaxelPainConceptsSickle cell diseaseHemoglobin sickle cell diseaseSickle cell crisisMetastatic diseasePainful crisesCell crisisBreast cancerAxillary lymph node dissectionPostmenopausal African-American womenLiver function test valuesLow-dose oxycodoneLymph node dissectionAxillary lymph nodesShortness of breathHistory of cancerSickle cell traitAfrican American womenRib painWeekly paclitaxelChemotherapy regimenNode dissectionSegmental mastectomyBone scanLeft breastLymph nodes
2004
Change in tumor cellularity of breast carcinoma after neoadjuvant chemotherapy as a variable in the pathologic assessment of response
Rajan R, Poniecka A, Smith TL, Yang Y, Frye D, Pusztai L, Fiterman DJ, Gal‐Gombos E, Whitman G, Rouzier R, Green M, Kuerer H, Buzdar AU, Hortobagyi GN, Symmans WF. Change in tumor cellularity of breast carcinoma after neoadjuvant chemotherapy as a variable in the pathologic assessment of response. Cancer 2004, 100: 1365-1373. PMID: 15042669, DOI: 10.1002/cncr.20134.Peer-Reviewed Original ResearchConceptsResidual tumor sizeCore needle biopsyNeoadjuvant chemotherapyTumor sizeResection specimensNeedle biopsyBreast carcinomaTumor cellularityClinical responsePathologic responseControl groupDiagnostic core needle biopsyGreatest dimensionPrimary surgical managementResidual primary tumorResidual tumor categoriesComplete pathologic responseWeeks of diagnosisResidual tumor groupEosin-stained tissue sectionsCyclophosphamide chemotherapyPartial responsePathologic assessmentPathologic evaluationPathologic size
2002
Phase II Study of Weekly Docetaxel and Trastuzumab for Patients With HER-2–Overexpressing Metastatic Breast Cancer
Esteva FJ, Valero V, Booser D, Guerra LT, Murray JL, Pusztai L, Cristofanilli M, Arun B, Esmaeli B, Fritsche HA, Sneige N, Smith TL, Hortobagyi GN. Phase II Study of Weekly Docetaxel and Trastuzumab for Patients With HER-2–Overexpressing Metastatic Breast Cancer. Journal Of Clinical Oncology 2002, 20: 1800-1808. PMID: 11919237, DOI: 10.1200/jco.2002.07.058.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Agents, PhytogenicAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsDisease ProgressionDocetaxelDrug Administration ScheduleFemaleGene Expression Regulation, NeoplasticHumansIn Situ Hybridization, FluorescenceMiddle AgedPaclitaxelReceptor, ErbB-2TaxoidsTime FactorsTrastuzumabTreatment OutcomeUp-RegulationConceptsMetastatic breast cancerOverall response rateWeekly docetaxelBreast cancerPhase II studySecond-line therapyTrastuzumab-based therapyWeek of restExtracellular domain levelsII studyLoading doseMedian timeExcessive tearingFluid retentionECD concentrationsRepetitive dosingWeekly treatmentECD levelsPatientsTrastuzumabActive combinationResponse rateDocetaxelCancerAcute toxicity
1998
Daily Oral Etoposide in Patients With Heavily Pretreated Metastatic Breast Cancer
Pusztai L, Walters R, Valero V, Theriault R, Hortobagyi G. Daily Oral Etoposide in Patients With Heavily Pretreated Metastatic Breast Cancer. American Journal Of Clinical Oncology 1998, 21: 442-446. PMID: 9781596, DOI: 10.1097/00000421-199810000-00004.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAdultAgedAntineoplastic Agents, PhytogenicBreast NeoplasmsDrug Administration ScheduleEtoposideFemaleHumansMiddle AgedNeoplasm MetastasisSalvage TherapyConceptsGrade 4 toxicityMetastatic breast cancerSignificant hematologic toxicityOral etoposideBreast cancerGrade 2Hematologic toxicityDaily oral etoposideFourth-line agentZubrod performance statusPercent of patientsPhase II studyMajority of patientsGreater thrombocytopeniaNeutropenic feverStable diseasePrevious therapyRadiologic evidenceII studyMedian durationPartial responsePerformance statusMedian ageMore regimensSevere anemia